Studies showed that ELAVL1 promoted the progression of liver cancer [160], lung cancer [161–163], colorectal cancer [164–166], gastric cancer [36], esophageal cancer [167], breast cancer [168, 169], prostate cancer [170, 171], and ovarian cancer [172]. This evidence concerns the gene ELAVL1 and gastric cancer.